Welcome to our dedicated page for Zimmer Biomet SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zimmer Biomet’s filings rarely read like light literature—hundreds of pages detail knee, hip, and S.E.T. sales, FDA clearances, and the cost of bringing robotic surgery to market. Sorting through that volume to spot revenue shifts or a device-recall risk is a real challenge.
Stock Titan solves that problem. Our AI turns dense disclosures into plain language so you can understand Zimmer Biomet SEC documents with AI in minutes, not hours. Need to track Zimmer Biomet insider trading Form 4 transactions? We stream Form 4 insider transactions in real-time and flag unusual executive stock moves. Trying to compare margins across segments? The quarterly earnings report 10-Q filing is summarised automatically, while key trends are highlighted for fast Zimmer Biomet earnings report filing analysis.
You’ll find every form the moment it hits EDGAR�10-K annual report simplified, 8-K material events explained, proxy statement executive compensation breakdowns, and each Zimmer Biomet 8-K material events explained for device launches or recalls. Our platform layers AI-powered summaries, searchable text, and red-line comparisons so you can:
- Monitor Zimmer Biomet executive stock transactions Form 4 before material events
- Follow segment-level revenue trends across knees, hips, and robotics
- Review risk-factor changes without rereading 300 pages
Whether you’re an analyst asking “Where can I find Zimmer Biomet’s quarterly earnings report 10-Q filing?� or a surgeon-investor wondering “How to read Zimmer Biomet’s 10-K annual report�, our exhaustive library keeps you current with real-time updates and expert context. Complex orthopedic disclosures, explained simply.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) has entered into a definitive Agreement and Plan of Merger to acquire Monogram Technologies Inc. On 11 July 2025 the company and its wholly-owned subsidiary, Honey Badger Merger Sub, signed the merger agreement under which Merger Sub will be merged into Monogram, making Monogram a wholly-owned subsidiary of Zimmer Biomet at closing.
Transaction consideration will be paid entirely in cash plus a contractual contingent value right (CVR):
- Monogram common stockholders will receive $4.04 per share in cash plus one CVR.
- Series D preferred holders will receive $2.25 per share in cash plus any accrued but unpaid dividends.
- Series E preferred holders will receive $100.00 per share in cash.
The company furnished an investor presentation (Exhibit 99.1) and a joint press release (Exhibit 99.2); both are incorporated by reference but are deemed “furnished,� not “filed,� under the Exchange Act. Zimmer Biomet stresses that forward-looking statements in the materials are subject to numerous risks, including regulatory approvals, Monogram shareholder approval, competing offers, integration challenges, and potential termination fees.
No financial statements or pro-forma financial data were included in this Form 8-K. Closing timing and expected financial impact were not disclosed.
Mersana Therapeutics, Inc. (NASDAQ: MRSN) filed an 8-K to disclose the termination of its October 29, 2021 loan and security agreement with Oxford Finance LLC and other lenders. On July 1, 2025, the company paid approximately $17.9 million, which fully satisfied and discharged all outstanding indebtedness and related obligations under the agreement. As a result, the loan agreement and its related collateral security documents are no longer in effect.
The disclosure was made under Item 1.02 (“Termination of a Material Definitive Agreement�). No other material events, financial results, or operational updates were included in this filing.
On 2 July 2025, Enstar Group Limited (symbol: ESGR) and its financing subsidiary filed Post-Effective Amendment No. 1 to six previously effective Form S-3 shelf registration statements. The amendment follows the completion of a series of mergers, effective the same day, in which Enstar became a wholly owned subsidiary of Elk Bidco Limited. Because public offerings under these shelves have been terminated, the registrants are deregistering all securities that remained unsold under the following registration numbers: 333-270204, 333-220889, 333-215144, 333-195562, 333-151461 and 333-143064. No new securities are being offered, and no financial results are provided. Signatures were executed by Audrey B. Taranto (General Counsel) for Enstar Group Limited and Jennifer Miu (Chief Financial Officer) for Enstar Finance LLC.
Form 4 filing overview: Clover Health Investments (CLOV) reported insider activity by Jamie L. Reynoso, listed as “CEO, Medicare Advantage.� On 30 June 2025 Ms. Reynoso earned 217,523 Class A shares through the final tranche of a March 16 2023 performance-based RSU award. To satisfy withholding taxes, the company automatically sold 85,596 shares at $2.79 per share. After the automatic sale, Ms. Reynoso’s direct ownership stands at 3,328,328 Class A shares, up roughly 132 k shares versus the prior balance.
- Nature of transaction: “A� code denotes acquisition from equity award; “F� code denotes shares withheld for taxes—neither represents an open-market trade.
- Cost basis: RSUs were settled at no cash cost to the insider; only the tax-withholding sale carries a market price.
- Alignment impact: The executive retains a sizable equity stake (�3.3 million shares), reinforcing incentive alignment, but no new cash investment was made.
Overall, the filing reflects routine equity-compensation vesting and related tax withholding rather than a discretionary buy or sell decision. Market impact is expected to be neutral barring other catalysts.
Zimmer Biomet Holdings, Inc. (ZBH) � Form 4 filing dated 07/02/2025
Director Michael J. Farrell reported the automatic accrual of 466.469 phantom stock units on 06/30/2025 under the company’s Deferred Compensation Plan for Non-Employee Directors. Each unit is economically equivalent to one share of common stock at a reference price of $91.11; the units will be settled in cash within 60 days after Mr. Farrell ceases to serve on the board. Following the transaction, Mr. Farrell holds a total of 16,894.007 phantom stock units, classified as direct ownership. No non-derivative common shares were bought or sold, and there were no changes to Mr. Farrell’s voting power.
The filing does not disclose any open-market share purchases or sales, equity grants that dilute existing shareholders, or other events likely to affect near-term financial performance. Accordingly, the transaction appears routine and has limited market impact.
Lightwave Logic, Inc. (LWLG) Form 4 filing: Director Craig Ciesla was granted 80,645 restricted stock units (RSUs) on 06/30/2025 under the company’s 2025 Equity Incentive Plan at $0.00 exercise price. The award vests in four tranches: 20,162 RSUs on 07/15/2025 and 20,161 RSUs on each of 09/30/2025, 12/31/2025 and 03/31/2026, contingent on continued service. Following the grant, Ciesla’s total beneficial ownership equals 80,645 RSUs, all held directly. No common shares were sold or disposed of, so the filing signals no insider selling pressure. While the grant is non-cash and non-dilutive until vested and settled, the shares will add modest dilution when they convert to common stock.
OCI N.V. and its Dutch subsidiaries OCI Intermediate B.V. and OCI Chemicals B.V. have filed a Schedule 13G disclosing a sizeable passive stake in Methanex Corporation (NASDAQ/TSX: MEOH). The filing, triggered by a June 27 2025 event date, shows beneficial ownership of 9,944,308 common shares, equal to 12.9 % of Methanex’s 77,339,520 shares outstanding as of June 30 2025.
All shares are held with shared voting power over 7,726,218 shares � subject to an undertaking not to vote more than 9.99 % of the company’s outstanding stock until Toronto Stock Exchange listing conditions are satisfied � and shared dispositive power over the full 9.94 million-share position. The reporting persons possess no sole voting or dispositive authority, underscoring the filing’s passive intent. Each entity certifies that the securities were not acquired for the purpose of influencing control, in line with Schedule 13G requirements.
The disclosure makes OCI � a Netherlands-based global producer of nitrogen, methanol and hydrogen products � one of Methanex’s largest known shareholders. While the filing does not announce any transaction terms or strategic plans, the scale of the stake (worth roughly US$450-500 million at recent prices) signals institutional confidence in Methanex’s methanol market outlook and could foreshadow future collaboration or corporate activity within the global methanol value chain.
Expro Group Holdings N.V. (XPRO) filed a Form 4 disclosing equity grants to its newly reported Chief Financial Officer, Sergio L. Maiworm Jr. On 30 June 2025, the executive received two separate awards of restricted stock units (RSUs):
- 286,041 RSUs that cliff-vest on 30 June 2028.
- 42,792 RSUs that vest one-third each on 30 June 2026, 2027 and 2028.
The combined 328,833 RSUs represent the CFO’s entire reported beneficial ownership following the transactions. Both awards were granted as inducement awards under NYSE Rule 303A.08 and were acquired at $0 cost, implying no open-market purchase or sale of common stock. No derivative securities were involved, and no dispositions were reported.
The multi-year vesting schedules aim to encourage long-term value creation, while the issuance of new shares introduces a modest dilutive element. No other financial metrics, sales, or option exercises were disclosed in the filing.
Leidos Holdings, Inc. (LDOS) � Form 4 insider transaction
Chief Financial Officer Christopher R. Cage reported one transaction dated 06/30/2025.
- Acquisition: 64.1944 shares of common stock credited at $0.00 per share. The shares represent dividend-equivalent rights that were automatically reinvested in the company’s Key Executive Stock Deferral Plan.
- Post-transaction ownership: 29,288.682 indirect shares held via the deferral plan and 46,953 direct shares.
No derivative securities were involved and no sales were disclosed. The filing does not indicate any open-market purchases or dispositions; the recorded activity is routine and non-cash. Given the immaterial share amount relative to the executive’s existing holdings, the filing is unlikely to have a meaningful impact on LDOS’s share count or market perception.
FAQ
What is the current stock price of Zimmer Biomet (ZBH)?
What is the market cap of Zimmer Biomet (ZBH)?
What is Zimmer Biomet's primary focus?
How does Zimmer Biomet integrate technology into its products?
What are the major product categories offered by Zimmer Biomet?
How does Zimmer Biomet maintain its industry reputation?
What distinguishes Zimmer Biomet from its competitors?
In which global markets does Zimmer Biomet operate?
How does Zimmer Biomet support healthcare professionals?
What role do strategic partnerships and acquisitions play for Zimmer Biomet?
